In terms of broadening both access to treatment and stakeholder understanding, there remains plenty of room for growth for biosimilars in Europe, Medicines for Europe director general Adrian van den Hoven tells Generics Bulletin in an exclusive interview.
The European biosimilars industry was offered a boost by a recent affirmative statement from the European Medicines Agency and Heads of Medicines Agencies confirming the scientific rationale supporting the interchangeability of biosimilars and biologics, while momentum is also building in Europe to streamline regulatory processes governing biosimilars.
However, amid these positive developments there still remains room for the industry to help further broaden access to biologic treatments...
The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.
Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.
Formycon is preparing to start a new era – entering Latin America with its ranibizumab biosimilar, which is expected to be a “good contributor” to the firm’s finances.
